My title


Author's details

Name: Joyce Miller
Date registered: April 3, 2012

Latest posts

  1. Which oral anticoagulant for atrial fibrillation? — April 21, 2016
  2. Zika Virus and Pregnancy – Online First – NEJM — April 14, 2016
  3. Zika Virus — April 14, 2016
  4. Zika virus as a cause of neurologic disorders — April 14, 2016
  5. Mediterranean diet and fracture risk in postmenopausal women — March 29, 2016

Most commented posts

  1. “PubMed Clinic” – Learn how to use our intranet electronic medical library and tie it into PubMed searching — 1 comment
  2. Earn 2 CME credits! Come to a “Pubmed Clinic” — 1 comment

Author's posts listings

Which oral anticoagulant for atrial fibrillation?

by jmiller on April 21, 2016

Direct-to-consumer advertisements continue to urge patients who take warfarin for atrial fibrillation to ask their doctors about the benefits of one or another of the newer anticoagulants.  This review  (Medical Letter, April 11) addresses the efficacy, bleeding and reversibility of direct oral anticoagulants.  The article concludes that “the direct oral anticoagulants dabigatran (Pradaxa), apixaban (Eliquis), eoxaban (Savaysa, and rivaroxaban (Zarelto) have been at least as effective as warfarin (Coumadin, and others) in preventing stroke or systemic embolism in patients with nonvalvular atrial fibrillation, and they may appear to be safer.  Patients well-controlled on warfarin (INR stable in the therapeutic range) could stay on it.  For all others, one of the direct oral anticoagulants might be a better choice.  Head-to-head comparisons of the new drugs are lacking.”  Click here to read full text.